Report on Epigenomic Therapies Highlights Changes in Drug Development Priorities
By LabMedica International staff writers Posted on 02 Sep 2012 |
A report recently released to the biotech industry predicts sharp growth in research efforts to develop drugs for epigenomic therapies for cancer, cardiovascular diseases, and neurological dysfunctions.
The report, Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics, which was prepared by Kalorama Information (New York, NY, USA), indicates a major shift in thinking about how epigenomic therapies will be impacting drug development research priorities and budgets.
The report states that drugs that target the epigenome offer a number of important advantages over other forms of cancer treatment; most notably they can be taken orally, saving the patient discomfort, cost and inconvenience. They are also more focused specifically against their target.
“Rather than blasting away machine gun style at the malignancy, they aim at a very specific reaction site within the cell,” said the author of the report Dr. K. John Morrow, Jr., an analyst at Kalorama Information. “So far their side effects have proven to be relatively minor.”
“At present the major pharmaceutical companies are faced with a downward spiral of profitability,” said Dr. Morrow. “Epigenomic technologies represent an escape from this corrosive cycle of greater and greater R&D expenditures and poorer and poorer yields of FDA-approved pharmaceuticals.”
Related Links:
Kalorama Information
The report, Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics, which was prepared by Kalorama Information (New York, NY, USA), indicates a major shift in thinking about how epigenomic therapies will be impacting drug development research priorities and budgets.
The report states that drugs that target the epigenome offer a number of important advantages over other forms of cancer treatment; most notably they can be taken orally, saving the patient discomfort, cost and inconvenience. They are also more focused specifically against their target.
“Rather than blasting away machine gun style at the malignancy, they aim at a very specific reaction site within the cell,” said the author of the report Dr. K. John Morrow, Jr., an analyst at Kalorama Information. “So far their side effects have proven to be relatively minor.”
“At present the major pharmaceutical companies are faced with a downward spiral of profitability,” said Dr. Morrow. “Epigenomic technologies represent an escape from this corrosive cycle of greater and greater R&D expenditures and poorer and poorer yields of FDA-approved pharmaceuticals.”
Related Links:
Kalorama Information
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples